21 Apr 17:11
by Mirko Iubatti, Isabel Maicas Gabas, Lina M. Cavaco, Elnaz Harifi Mood, Ernest Lim, Federica Bonanno, Niloofar Yavari, Camilla Brolin, and Peter E. Nielsen

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.2c00089
20 Apr 19:19
by Xiaohui Zhao, Xinglin Yang, and Howard C. Hang

Biochemistry
DOI: 10.1021/acs.biochem.1c00758
20 Apr 19:18
by Daniel J. Brogan and Omar S. Akbari

Biochemistry
DOI: 10.1021/acs.biochem.2c00051
20 Apr 19:12
by Suraj Toraskar, Preeti Madhukar Chaudhary, and Raghavendra Kikkeri

ACS Chemical Biology
DOI: 10.1021/acschembio.1c00998
28 Mar 13:00
by Phuong Luong, Antara Ghosh, Karen D. Moulton, Suvarn S. Kulkarni, and Danielle H. Dube

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.2c00060
13 Mar 07:30
by Sujeet Kumar, Aurelio Mollo, Daniel Kahne, and Natividad Ruiz

Chemical Reviews
DOI: 10.1021/acs.chemrev.1c00773
11 Feb 18:58
by Michael A. Lobritz, Ian W. Andrews, Dana Braff, Caroline B.M. Porter, Arnaud Gutierrez, Yoshikazu Furuta, Louis B.G. Cortes, Thomas Ferrante, Sarah C. Bening, Felix Wong, Charley Gruber, Christopher W. Bakerlee, Guillaume Lambert, Graham C. Walker, Daniel J. Dwyer, James J. Collins
Lobritz et al. assess the target-proximal and downstream metabolic consequences of treatment of E. coli with the β-lactam mecillinam. They show that lethality from PBP2 inhibition is a specific consequence of toxic metabolic shifts induced by energy demand from multiple catabolic and anabolic processes.
17 Nov 14:48
by Andrea Olga Papadopoulos
PLoS One. 2021 Nov 16;16(11):e0259181. doi: 10.1371/journal.pone.0259181. eCollection 2021.
ABSTRACT
Mycobacterium tuberculosis, the causative agent of tuberculosis remains a global health concern, further compounded by the high rates of HIV-TB co-infection and emergence of multi- and extensive drug resistant TB, all of which have hampered efforts to eradicate this disease. As a result, novel anti-tubercular interventions are urgently required, with the peptidoglycan component of the M. tuberculosis cell wall emerging as an attractive drug target. Peptidoglycan M23 endopeptidases can function as active cell wall hydrolases or degenerate activators of hydrolases in a variety of bacteria, contributing to important processes such as bacterial growth, division and virulence. Herein, we investigate the function of the Rv0950-encoded putative M23 endopeptidase in M. tuberculosis. In silico analysis revealed that this protein is conserved in mycobacteria, with a zinc-binding catalytic site predictive of hydrolytic activity. Transcript analysis indicated that expression of Rv0950c was elevated during lag and log phases of growth and reduced in stationary phase. Deletion of Rv0950c yielded no defects in growth, colony morphology, antibiotic susceptibility or intracellular survival but caused a reduction in cell length. Staining with a monopeptide-derived fluorescent D-amino acid, which spatially reports on sites of active PG biosynthesis or repair, revealed an overall reduction in uptake of the probe in ΔRv0950c. When stained with a dipeptide probe in the presence of cell wall damaging agents, the ΔRv0950c mutant displayed reduced sidewall labelling. As bacterial peptidoglycan metabolism is important for survival and pathogenesis, the role of Rv0950c and other putative M23 endopeptidases in M. tuberculosis should be explored further.
PMID:34784363 | PMC:PMC8594824 | DOI:10.1371/journal.pone.0259181
16 Nov 15:08
by Apurva Panjla, Grace Kaul, Sidharth Chopra, Alexander Titz, and Sandeep Verma

ACS Chemical Biology
DOI: 10.1021/acschembio.1c00626
15 Nov 22:55
by Montserrat Mora-Ochomogo
RSC Med Chem. 2021 Aug 4;12(10):1623-1639. doi: 10.1039/d1md00200g. eCollection 2021 Oct 20.
ABSTRACT
The β-lactams are the most widely used antibacterial agents worldwide. These antibiotics, a group that includes the penicillins and cephalosporins, are covalent inhibitors that target bacterial penicillin-binding proteins and disrupt peptidoglycan synthesis. Bacteria can achieve resistance to β-lactams in several ways, including the production of serine β-lactamase enzymes. While β-lactams also covalently interact with serine β-lactamases, these enzymes are capable of deacylating this complex, treating the antibiotic as a substrate. In this tutorial-style review, we provide an overview of the β-lactam antibiotics, focusing on their covalent interactions with their target proteins and resistance mechanisms. We begin by describing the structurally diverse range of β-lactam antibiotics and β-lactamase inhibitors that are currently used as therapeutics. Then, we introduce the penicillin-binding proteins, describing their functions and structures, and highlighting their interactions with β-lactam antibiotics. We next describe the classes of serine β-lactamases, exploring some of the mechanisms by which they achieve the ability to degrade β-lactams. Finally, we introduce the l,d-transpeptidases, a group of bacterial enzymes involved in peptidoglycan synthesis which are also targeted by β-lactam antibiotics. Although resistance mechanisms are now prevalent for all antibiotics in this class, past successes in antibiotic development have at least delayed this onset of resistance. The β-lactams continue to be an essential tool for the treatment of infectious disease, and recent advances (e.g., β-lactamase inhibitor development) will continue to support their future use.
PMID:34778765 | PMC:PMC8528271 | DOI:10.1039/d1md00200g